全文获取类型
收费全文 | 163011篇 |
免费 | 33064篇 |
国内免费 | 2454篇 |
专业分类
耳鼻咽喉 | 5335篇 |
儿科学 | 5683篇 |
妇产科学 | 2672篇 |
基础医学 | 4945篇 |
口腔科学 | 1841篇 |
临床医学 | 27519篇 |
内科学 | 50824篇 |
皮肤病学 | 7795篇 |
神经病学 | 15425篇 |
特种医学 | 6768篇 |
外科学 | 43245篇 |
综合类 | 266篇 |
现状与发展 | 72篇 |
一般理论 | 1篇 |
预防医学 | 7335篇 |
眼科学 | 3497篇 |
药学 | 1930篇 |
中国医学 | 47篇 |
肿瘤学 | 13329篇 |
出版年
2024年 | 515篇 |
2023年 | 4844篇 |
2022年 | 1320篇 |
2021年 | 3285篇 |
2020年 | 6140篇 |
2019年 | 2343篇 |
2018年 | 7539篇 |
2017年 | 7490篇 |
2016年 | 8587篇 |
2015年 | 8581篇 |
2014年 | 15688篇 |
2013年 | 15907篇 |
2012年 | 6013篇 |
2011年 | 6065篇 |
2010年 | 10714篇 |
2009年 | 14549篇 |
2008年 | 6333篇 |
2007年 | 4688篇 |
2006年 | 7183篇 |
2005年 | 4468篇 |
2004年 | 3752篇 |
2003年 | 2673篇 |
2002年 | 2803篇 |
2001年 | 4225篇 |
2000年 | 3465篇 |
1999年 | 3626篇 |
1998年 | 3803篇 |
1997年 | 3611篇 |
1996年 | 3516篇 |
1995年 | 3315篇 |
1994年 | 2044篇 |
1993年 | 1657篇 |
1992年 | 1725篇 |
1991年 | 1723篇 |
1990年 | 1335篇 |
1989年 | 1485篇 |
1988年 | 1258篇 |
1987年 | 1095篇 |
1986年 | 1131篇 |
1985年 | 992篇 |
1984年 | 680篇 |
1983年 | 648篇 |
1982年 | 586篇 |
1981年 | 457篇 |
1980年 | 400篇 |
1979年 | 411篇 |
1978年 | 421篇 |
1977年 | 473篇 |
1975年 | 331篇 |
1972年 | 363篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
103.
104.
Toshio Kushiro Hiroshige Itakura Yoshihisa Abo Hiromi Gotou Shinji Terao Deborah L Keefe 《Hypertension research》2006,29(12):997-1005
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients with hypertension. Forty hundred and fifty-five Japanese men and women with a mean sitting diastolic blood pressure of 95-110 mmHg were randomized to receive once-daily double-blind treatment for 8 weeks with aliskiren 75, 150 or 300 mg or placebo. Aliskiren produced significant, dose-dependent reductions in mean sitting diastolic blood pressure (p<0.0005 vs. placebo for each dose) and mean sitting systolic blood pressure (p<0.001 vs. placebo for each dose). The placebo-corrected reductions in mean sitting systolic/diastolic blood pressure were 5.7/4.0, 5.9/4.5 and 11.2/7.5 mmHg in the aliskiren 75, 150 and 300 mg groups, respectively. After 8 weeks' treatment, 27.8%, 47.8%, 48.2% and 63.7% of patients in the placebo and aliskiren 75, 150 and 300 mg groups, respectively, achieved a successful treatment response (diastolic blood pressure <90 mmHg and/or reduced by > or =10 mmHg from baseline; p<0.005 vs. placebo for each dose). Aliskiren treatment was well tolerated, with the incidence of adverse events reported in the active treatment groups (53-55%) being similar to that in the placebo group (50%). This study, which is the first to assess the antihypertensive efficacy and safety of aliskiren in Japanese patients with hypertension, demonstrates that the once-daily oral renin inhibitor aliskiren provides significant, dose-dependent reductions in blood pressure with placebo-like tolerability. 相似文献
105.
Hideki Kawaguchi Kazuko Masuo Tomohiro Katsuya Ken Sugimoto Hiromi Rakugi Toshio Ogihara Michael L Tuck 《Hypertension research》2006,29(12):951-959
High blood pressure (BP) is a major determinant of cardiovascular events in obesity. The beta2- and beta3-adrenoceptor polymorphisms are associated with obesity and hypertension. In the present study, we examine the relationships of beta2- and beta3-adrenoceptor polymorphisms with further weight gain-induced BP elevation in obese subjects. Changes in BP, body weight, total body fat-mass, waist-to-hip ratio, plasma norepinephrine (NE) and leptin levels, and beta2(Arg16Gly)- and beta3(Trp64Arg)-adrenoceptor polymorphisms were measured periodically over a 5-year period in 55 entry obese (body mass index [BMI]> or =25.0 kg/m(2)) normotensive (BP<140/90 mmHg) men. BP elevation and weight gain were defined as > or =10% increases from entry levels over 5 years in mean BP or BMI. Obese subjects with weight gain, BP elevation or weight gain-induced BP elevation had higher frequencies of the Gly16 allele of Arg16GIy and Arg64 allele of Trp64Arg. Subjects carrying the Gly16 or Arg64 alleles had significantly greater total fat-mass and waist-to-hip ratio at entry and over a 5-year period compared to the subjects who did not carry these polymorphisms. Subjects carrying the Gly16 allele had similar levels of plasma NE, higher levels of plasma leptin and a lower slope of the regression lines between plasma leptin and NE levels. Those carrying the Arg64 allele had higher plasma NE levels at entry and over a 5-year period compared to the subjects without the Arg64 allele, but plasma leptin levels and slopes were similar. The findings demonstrate that the Arg64 allele of the beta3-adrenoceptor polymorphisms relates to weight gain-induced BP elevation accompanying high plasma NE (heightened sympathetic activity) in obese men. The Gly16 allele of the beta2-adrenoceptor polymorphisms links to weight gain-induced BP elevation associated with leptin resistance. beta2- and beta3-adrenoceptor polymorphisms could predict the future BP elevation and further weight gain-induced BP elevation in originally obese subjects. 相似文献
106.
Bo Jørgensen MD ; Gitte Juel Friis PhD ; Finn Gottrup MD DMSci 《Wound repair and regeneration》2006,14(3):233-239
Wound pain is a serious problem for elderly patients suffering from chronic leg ulcers, and it may lead to reduced wound healing rates and reduced quality of life. Biatain-Ibu Non-adhesive (Coloplast A/S), a new pain-reducing moist wound healing dressing containing ibuprofen was tested for pain reduction, safety, and efficacy on 10+2 patients in a single-blinded crossover study against Biatain Non-adhesive (Coloplast A/S). Pain was measured with a Numeric Box Scale before, during, and after dressing change. Quality of life was measured using the World Health Organization-5 Well-Being Index. Dressing moist wound healing properties such as absorption capacity and leakage were tested together with assessment of wound exudate and blood plasma content of ibuprofen. Use of the Biatain-Ibu foam dressing correlated with a decrease in pain intensity scores from 7 in the run-in period to approximately 2.5 in the Biatain-Ibu treatment phase. Quality of life measures were improved which together with the reduced pain could contribute to faster wound healing. The moist wound healing properties of Biatain-Ibu were similar to that of the Biatain Non-adhesive and ulcer size was reduced by 24% during the treatment period. Neither side effects nor systemic plasma concentrations of ibuprofen were observed. These data indicate that Biatain-Ibu could reduce persistent and temporary wound pain, increase Quality of life, was found safe to use, and had excellent moist wound healing properties. 相似文献
107.
108.
109.
110.